Boson Rapid Test for COVID19 *20/box* Health Canada Approved - FREE SHIPPING

SaniChoice

Reduced price $ 105.00 regular price $ 115.00

IN STOCK. FREE DELIVERY 2-3 BUSINESS DAYS. 

20 Tests per box. 2 bottles of solution per box.

High Accuracy: Boson tests are among the most accurate rapid antigen tests in the world. 

Antigen rapid test approved by Health Canada. 

Final sale, no exchanges or refunds.

Product Information:
Quantity: 20 tests/kit

Specimen Type: Nasopharyngeal Swab
Storage temperature: 2-30°C
Shelf life: 18 months
Test duration: 15-20 minutes

The kit contains
20 SARS-CoV-2 antigen rapid test cards
2 bottles of solution (1 bottle for 10 tests)
20 sterilized nasopharyngeal swabs
20 extraction tubes
1 User manual
1 Tube rack (for 6 tubes/rack)

 

CLINICAL TESTS RESULTS:

Sensitivity = 30/32×100% = 93,75% (95% CI: 85,36% - 99,99%)

Specificity = 200/204×100% = 98,04% (95% CI: 96,14% - 99,94%)

Accuracy = 230/236×100% = 97,46% (95% CI: 95,45% - 99,47%)

Usage:

The SARS-CoV-2 Rapid Antigen Test Card is a lateral flow immunoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid protein in nasal or nasopharyngeal swab specimens from suspected COVID individuals -19 by their health care provider within the first 7 days of symptom onset.

The results relate to the identification of the SARS-CoV-2 nucleocapsid protein. Antigen is usually detectable in nasal swab or nasopharyngeal swab specimens during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definitive cause of the disease.

Negative results should be treated as presumptive and do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including control decisions infections. Negative results should be considered in the context of the patient's recent exposures, history, and presence of clinical signs and symptoms consistent with COVID-19, and confirmed by molecular testing, if necessary, for management of the patient.

The SARS-CoV-2 Antigen Rapid Test Card is intended for use by trained clinical laboratory personnel specifically instructed and trained in in vitro diagnostic procedures.

By purchasing this product, you agree to follow the manufacturer's intended use and this site's terms of sale.

DOCUMENTS HERE:

Instructions

datasheet

Health Canada Approval

Sanichoix disclaims all liability arising from the use of this product. Do not use this test for Canadian travel requirements. A positive result does not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions.